Kornimate/medical-research-clean huggingface dataset:
augmenting flortaucipir dosimetry estimates

Conditions: Alzheimer's Disease

Summary: this study will obtain data from urine in subjects administered flortaucipir in an avid-sponsored study to augment the calculation of radiation dosimetry estimates.


Eligibility criteria:
inclusion criteria: * subjects who passed screening in an avid-sponsored study in which flortaucipir will be administered exclusion criteria: * subjects who have withdrawn informed consent * investigator or sponsor believes it is in the best interest of the subject to be removed from the trials
safety, tolerability and efficacy of two doses of once daily p2b001 in subjects with early parkinson's disease

Conditions: Parkinson's Disease

Summary: this study will evaluate an oral fixed-dose, once daily product that combines pramipexole and rasagiline for the treatment of early parkinson's disease. animal studies support the therapeutic advantage of combining low doses of rasagiline and pramipexole and suggest further improvement when both are administered in a sustained fashion. both rasagiline and pramipexole are well known marketed drugs for parkinson's disease with a good safety profile. combining the drugs in low doses and controlled release may provide better symptom management than the existing drugs alone or together.


Eligibility criteria:
inclusion criteria: * subject is male or female ≥35 years of age to ≤75 years of age at the time of enrollment. * subject has idiopathic parkinson's disease consistent with the uk brain bank criteria; must have bradykinesia with sequence effect and rest tremor or prominent motor asymmetry. * subject with disease duration no longer than 3 years and 0 months. * subject has a hoehn \& yahr (h\&y) stage score of \< 3. * subject has a mmse score ≥ 26 exclusion criteria: * subject has an atypical parkinsonian syndrome or secondary parkinsonism (e.g., due to drugs, metabolic neurogenetic disorders, encephalitis, cerebrovascular disease or degenerative disease). * subject has a history of psychosis or hallucinations within the previous 12 months. * subject who is taking anticholinergic drugs. * subject has previous exposure to levodopa or a dopamine agonist for longer than 4 weeks; if previous exposure was less than 4 weeks then it must not be within 2 months prior to the baseline visit. * subject has previous exposure to a mao-b inhibitor for longer than 4 weeks; if previous exposure was less than 4 weeks then it must not be within 3 months prior to the baseline visit. * subject who is taking mao inhibitors, potent cyp1a2 inhibitors, e,g, ciprofloxacin, dextromethorphan or antitussive agent, analgesic agents such as tramadol, meperidine, methadone and propoxyphene, strong 3a4 inducers, e.g., st. john's wort or cyclobenzaprine (tricyclic muscle relaxant), dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide. probenecid, cimetidine, ranitidine, diltiazem, verapamil and quinidine.

Keywords: parkinson's disease, rasagiline, pramipexole
repositioning immunotherapy in vetarans with lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: this study is a multicenter phase ii single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable stage iii nsclc.


Eligibility criteria:
inclusion criteria: * participants must be more than 18 years of age. * patient must have a performance status of 0-1 (ecog performance scale). * patient must be a candidate for concurrent chemoradiation. * unresectable stage iii nsclc as assessed by investigator or multidisciplinary tumor board assessment * pd-l1 tumor expression greater than or equal to 1% * presence of measurable disease according to recist v1.1 * adequate organ function * available tissue (archival ffpe preferred) with adequate tumor content ( 20% tumor cellularity). exclusion criteria: * active autoimmune disease that has requires immunosuppressive therapy in the previous year. * uncontrolled primary or acquired immunodeficiency (including hiv) * baseline corticosteroid usage (\>10 mg prednisone or equivalent daily) aside from supportive medication use. * tumor with known egfr, alk, ros1, met or ret mutations/fusions. * presence of significant comorbidities precluding participation in a clinical study as determined by investigator. * prior thoracic radiotherapy or prior systemic treatment for stage iiib/iv nsclc * has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. * is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with informed consent through 180 days after the last dose of trial treatment. * has a known history of active tb (bacillus tuberculosis) * has known active hepatitis b or hepatitis c. * has received a live vaccine within 30 days of enrollment. * known diagnosis of interstitial lung disease * inability to provide informed consent.
opioids and esophageal function

Conditions: Pharyngeal Dysfunction; Esophageal Dysfunction

Summary: the purpose of this study is to evaluate if opioid-induced effects on the pharynx and esophagus is centrally or peripherally mediated.

opioids induce pharyngeal and esophageal dysfunction and reduce the lower esophageal sphincter (les) pressure, and thereby decreases the barrier pressure between the stomach and esophagus. this contributes to an increased risk of regurgitation and aspiration during anaesthesia induction and in the postoperative period, when the patient is treated with opioids for pain relief. the effects of opioid antagonists on the opioid induced pharyngeal dysfunction and lower esophageal sphincter pressure are unknown. therefore it is of great clinical value to evaluate if these negative effects are reversed by peripheral opioid antagonist, methylnaltrexone. methylnaltrexone is one of the newer agents of peripherally acting opioid antagonists that act to reverse some of the side effects of opioid drugs, such as constipation, without affecting analgesia. if the opioid induced pharyngeal and esophageal dysfunction and reduction of the lower esophageal sphincter pressure is peripherally induced or mediated via peripheral opioid receptors, methylnaltrexone might reverse these effects and thereby reduce postoperative morbidity by reducing pulmonary complications. on the other hand, if the dysfunction is centrally induced and not mediated via peripheral opioid receptors there is no effect of methylnaltrexone. the pharyngeal and esophageal motility/function can be registered in an easy and objective way with the high resolution manometry, manoscan 360. manoscan 360 is an equipment with 36 sensors at 1 cm spacing with 12 tip transducers at every sensor. the 36 closely spaced sensors automatically capture all relevant motor function from the pharynx to the stomach. the system collects reliable and consistent data records with improved diagnostic accuracy, and the data are analyzed using manoview analyzes software. manoscan 360 has a ce mark approval and has been used at örebro university hospital during the last two years.

Eligibility criteria:
inclusion criteria: * 18 -40 year old healthy volunteers from both sexes. * have signed and dated informed consent. * willing and able to comply with the protocol for the duration of the trial. exclusion criteria: * anamnesis of pharyngoesophageal dysfunction. * known or history of cardiac, pulmonary or neurological disease. * ongoing medication. * allergies to or history of reaction to methylnaltrexone, remifentanil or fentanyl analogues. * pregnancy or breast feeding. * participation in another clinical medicinal trial during the last 30 days or where follow-up is not completed.

Keywords: methylnaltrexone upper esophageal sphincter lower esophageal sphincter high resolution solid state manometry opioid induced pharyngeal and esophageal dysfunction
effectiveness of core stabilization exercise in patients with subacute non-specific low back pain

Conditions: Low Back Pain

Summary: the purpose of this study is to examines the effectiveness of core stabilization exercise on pain intensity at rest, functional disability, lumbar movement and ability to perform repositioning tasks (joint position sense) in patients with subacute non-specific low back pain.

this study is to compare the effectiveness of core stabilization exercise and physical therapy on pain intensity at rest, functional disability, lumbar movement and ability to perform repositioning tasks (joint position sense) in patients with subacute non-specific low back pain. there are 2 groups receiving 2 different kinds of intervention: treatment group receiving core stabilization exercise (cse) and control group receiving physical therapy including therapeutic ultrasound and hydrocollator pack. each intervention will perform for 7 weeks. the patients will assess for all outcome measures at baseline, 7 weeks of intervention, and 1- month follow-up

Eligibility criteria:
inclusion criteria: * onset of back pain within 6 -12 weeks participants had no history of back pain for a period of 6 months prior to the current episode. * pain intensity measure by a numerical rating scale (0-10 nrs) and a score of pain at least 3 out of 10. * never receive the treatment by core stabilization exercise (cse) during 3 months before participate in this study. exclusion criteria: * pregnancy * onset of serious spinal pathology: spinal fracture, spinal tumor or spinal infection. * cauda equina syndrome. * presented at least 2 out of 3 signs of neurological deficit
the percentage of cases of acute treatment with allopurinol in gout patients

Conditions: Gout

Summary: the aim of the study is to determine the percentage of cases of acute treatment with allopurinol in gout patients who have been previously treated.


Eligibility criteria:
inclusion criteria: * gout patients exclusion criteria: * pregnant women * chronic renal failure * patients with allopurinal hypersensitivity
study to estimate how common it is to have genetic variants associated with nafld

Conditions: Healthy

Summary: the purpose of this study is to estimate the prevalence of genetic variants associated with liver disease in participants who are known, or are likely to have nafld.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormality based on medical history, physical exam, and 12-lead electrocardiogram (ecg) collected during visit 1 * women must be of non-childbearing potential, defined as either: a.) postmenopausal or b.) permanently sterile * must be willing to provide a deoxyribonucleic acid (dna) sample for assessment of genetic variants associated with nafld * must sign an informed consent form (icf) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study exclusion criteria: * history or presence of drug abuse within the 2 years prior to visit 1 * excessive use of alcohol within 2 years prior to the study * body mass index greater than (\>) 40 kilogram per meter square (kg/m\^2) * evidence of other active (acute or chronic) liver disease other than nafld/ nonalcoholic steatohepatitis (nash) * history of bariatric surgery or planning to undergo bariatric surgery within the next year * inability to undergo magnetic resonance imaging (mri)
study to evaluate the pk of po omadacycline in adults with community-acquired bacterial pneumonia

Conditions: Community-acquired Pneumonia

Summary: the purpose of this study is to evaluate the pharmacokinetics of an oral omadacycline dosing regimen in the treatment of adults with cabp.


Eligibility criteria:
inclusion criteria: * male or female participants, age 18 or older who have signed the informed consent form * must have a qualifying community-acquired bacterial pneumonia * has disease severity such that oral antibiotics therapy is appropriate * participants must not be pregnant at the time of enrollment * must agree to a reliable method of birth control during the study and for 30 days following the last dose of study drug * must be able to swallow tablets and comply with all of the requirements of the study exclusion criteria: * has received more than 24 hours of a potentially effective systemic antibacterial therapy within the 72 hours prior to the first dose of test article * known or suspected infection caused by a pathogen that may be resistant to test article * participants who reside in a long-term care or nursing home * evidence of empyema * evidence of significant immunological disease * evidence of liver impairment or disease * evidence of unstable cardiac disease * severe renal disease or requirement for dialysis * evidence of septic shock * has a history of hypersensitivity or allergic reaction to any tetracycline * has received an investigational drug within the past 30 days * participants who are pregnant or nursing * unable or unwilling to comply with the protocol requirements
detection of renal malignancy of complicated renal cysts

Conditions: Kidney Neoplasm; Cysts; Carcinoma, Renal Cell

Summary: the aim of this study was to show additional diagnostic criteria of computed tomography (ct) scan to diagnose and predict the detection and recurrence of cystic renal cell carcinoma in the patients with complicated renal cysts. furthermore, we would demonstrate the relationship between complicated renal cysts diagnosed by bosniak system and some parameters of pathological results. the analysis about detection time of renal malignancy would help determine the practical guidelines of follow-up plan for complicated renal cysts.

even though there have been many trials and errors to enhance the diagnostic accuracy of ct scans for complicated cysts, the trial to obtain the enhanced accuracy using ct scan would be still valuable, when we consider its widespread use. a previous study demonstrated that the enhancement of hu with intravenous administration of contrast material on ct scan by 15 hu would be "almost always indicative of a pathologic process although not always a malignancy", another study showed the cut-off as 42 or 47 hu gap would be helpful in the prediction of renal malignancy.

Eligibility criteria:
inclusion criteria: * all patients who were diagnosed as renal cysts * available serial follow-up data of ct scan * all ct imaging included non-enhanced (nep), corticomedullary (cmp), and early excretory phase (eep) scans. the scan delay times should range from 30 to 40 seconds for cmp scans and from 120 to 180 seconds for eep scans. exclusion criteria: * cases diagnosed by only us/mr * no serial ct images * cysts of autosomal dominant adult polycystic kidney disease * cysts less than 1cm in diameter (difficult to evaluate accurately) * follow-up period less than 1 yr in the patients who had no surgery
clinical relationship between vitamin d-mediated th17 and treg cells and parkinson's disease

Conditions: Neurology; Immunology

Summary: the aim of this study is to detect the expression levels of vitamin d, treg, and th17 in the peripheral blood of patients with parkinson\&#39;s disease (pd), investigate the impact of treg/th17 imbalance on pd patients, and explore the effects of vitamin d intervention on treg/th17 imbalance and clinical outcomes. furthermore, this study aims to delve into the potential mechanisms of vitamin d deficiency and treg/th17 imbalance in the pathogenesis of parkinson\&#39;s disease, ultimately providing new theoretical evidence for the research, prevention, and treatment of pd.

fromjanuary 2023 to july 2024, 50 pd patients and 50 health control groups were collected. all subjects were from the parkinson\&#39;s outpatient clinic and ward of the department of neurology, suzhou hospital affiliated to anhui medical university. this study was approved by the medical ethics committee of suzhou municipal hospital and signed an informed consent form. the gender, age, identity registration, place of origin, marital status, education level, occupation, smoking, drinking, occupational exposure, body mass index, home address and contact information of the patients were collected for detailed registration. current medical history, past history, family history, medication use, physical examination, previous relevant auxiliary examination results, etc. evaluation scales: h-y staging scale, updrs scale, breg balance scale, mmse intelligence scale, moca scale, sds depression self-rating scale, sas anxiety self-rating scale, pdss parkinson\&#39;s disease sleep scale. peripheral blood of patients and control groups were sampled to determine the levels of vitamin d, treg and th17. pd patients were divided into vitamin d deficiency group and vitamin d non-deficiency group according to the detection of vitamin d. vitamin d deficiency group was randomly divided into intervention group and non-intervention group. the intervention group was supplemented with vitamin d, and the non-intervention group was not treated. the above scale and peripheral blood vitamin d, treg and th17 levels were evaluated after 3 months of follow-up and compared with the pre-intervention and non-intervention groups. statistical analysis was carried out using spss26.0 and graphpad prism v.9.

Eligibility criteria:
inclusion criteria: * meets the age requirement and is in good health. exclusion criteria: * have related vitamin d metabolic diseases (kidney failure, severe liver damage, hereditary 1α hydroxylase deficiency, etc.). * have an immune system disorder. * have a history of disabling cerebrovascular disease. * have a grade 1 or 2 relative with pd. * have severe dementia, depression, or serious mental illness. * failure to sign the informed consent form.

Keywords: parkinson's disease vitamin d treg th17
vestibular function using mitochondrial antioxidant therapy

Conditions: Vestibular Function Disorder

Summary: to determine if supplementation with known mitochondrial antioxidants (alpha lipoic acid (ala) and coq-10) will stabilize or improve vestibular function in older adults.

the subjects will be divided into two groups, half will be given daily supplementation with ala and coq-10. the second group will only receive standard of care treatment, with no study drug intervention.

Eligibility criteria:
inclusion criteria: 1. community dwelling non-gender specific aged 65-90 years of age 2. for female subjects, confirm that they are post-menopausal 3. diagnosed with vestibular dysfunction 4. able to provide informed consent 5. prepared to adhere to study drug regimen and attend all study visits exclusion criteria: 1. unable to provide informed consent 2. allergy/sensitivity to the study drugs or any of their ingredients 3. unable to adhere to study drug regimen or to attend study visits. 4. current or past participation within a specified timeframe in another clinical trial, as warranted by the administration of this intervention. 5. current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. 6. anticoagulant drugs: anisindione (miradon), dicumarol and warfarin (coumadin and jantoven) 7. participants who are currently undergoing treatment with insulin, levothyroxine or chemotherapy drugs. 8. participants who are undergoing treatment with theophylline.

Keywords: alpha lipoic acid coq10
a study of primary prophylaxis with neulasta (pegfilgrastim) versus secondary prophylaxis after chemotherapy in elderly subjects (>/= 65 years old) with cancer

Conditions: Neutropenia; Breast Cancer; Lung Cancer; Non-Hodgkin's Lymphoma; Ovarian Cancer

Summary: the purpose of this study is to assess pegfilgrastim starting with the first cycle versus secondary prophylaxis on neutropenic events (including neutropenia +/- fever, dose delays, dose reductions, and hospitalizations) in older patients receiving chemotherapy.


Eligibility criteria:
inclusion criteria: * \>/= 65 years old * documented diagnosis of lung, breast, or ovarian cancer, or nhl * scheduled to receive one of 15 standard chemotherapy regimens * chemotherapy naive or have received adjuvant therapy and/or have no more than one regimen of chemotherapy for metastatic disease * life expectancy of at least 3 months * ecog performance status \</=2 * adequate renal and hematologic function * informed consent for participation in the study prior to any study specific procedures exclusion criteria: * known hypersensitivity to any of the products to be administered during dosing * primary prophylactic antibiotics in all cycles * prior radiation therapy within 2 weeks of randomization into this study or plan for radiation therapy during study participation, except for spot radiation for bony metastases * prior bone marrow or stem cell transplant or plan to receive any transplant therapy during study participation * clinically symptomatic brain metastases * folstein mini-mental state exam score \<18 * any premalignant myeloid condition or any malignancy with myeloid characteristics * history of prior malignancy within the last 5 years other than subject's original cancer diagnosis listed in inclusion criteria with the exception of curatively treated basal cell carcinoma, squamous cell carcinoma, in situ cervical carcinoma or surgically cured malignancies * unstable/uncontrolled cardiac conditions or hypertension * active infection * subject is currently enrolled or has not yet completed at least 30 days since ending other investigational device or drug trial or is receiving other investigational agents
construction and evaluation of the liquid biopsy-based early diagnostic model for lung cancer

Conditions: Healthy; Pulmonary Nodule

Summary: the purpose of this study is to detetct circulating tumor cells(ctcs) and cancer associated macrophage-like cells (camls) in patients with pulmonary nodules using a novel microfluidic ctc-detection system. then construct an early diagnostic model for lung cancer.

patients found pulmonary nodules by ct screening will be enrolled in this study prospectively. ctcs and camls both are cancer specific biomarkers found in the peripheral blood of patients with solid tumors including lung cancer. through detecting ctcs and camls in healthy volunteers and patients with pulmonary nodules who undergo biopsy, determine the cut-off value of the test. further analysis of the test specificity and sensitivity, and on this basis construct an early diagnostic model for lung cancer.

Eligibility criteria:
inclusion criteria: * female or male, 18 years of age or older * pulmonary nodules diagnosed by chest ct or low-dose computed tomography (ldct) scans exclusion criteria: * prior diagnosis of lung cancer or other invasive malignancy within the past 5 years